EP1331011A3 - Derivatized oligonucleotides having improved uptake and other properties - Google Patents
Derivatized oligonucleotides having improved uptake and other properties Download PDFInfo
- Publication number
- EP1331011A3 EP1331011A3 EP03076286A EP03076286A EP1331011A3 EP 1331011 A3 EP1331011 A3 EP 1331011A3 EP 03076286 A EP03076286 A EP 03076286A EP 03076286 A EP03076286 A EP 03076286A EP 1331011 A3 EP1331011 A3 EP 1331011A3
- Authority
- EP
- European Patent Office
- Prior art keywords
- nucleoside
- substituent
- molecule
- properties
- linking group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78237491A | 1991-10-24 | 1991-10-24 | |
US782374 | 1991-10-24 | ||
EP92923139A EP0724447B1 (en) | 1991-10-24 | 1992-10-23 | Derivatized oligonucleotides having improved uptake |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP92923139A Division EP0724447B1 (en) | 1991-10-24 | 1992-10-23 | Derivatized oligonucleotides having improved uptake |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1331011A2 EP1331011A2 (en) | 2003-07-30 |
EP1331011A3 true EP1331011A3 (en) | 2003-12-17 |
Family
ID=25125854
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03076286A Withdrawn EP1331011A3 (en) | 1991-10-24 | 1992-10-23 | Derivatized oligonucleotides having improved uptake and other properties |
EP92923139A Expired - Lifetime EP0724447B1 (en) | 1991-10-24 | 1992-10-23 | Derivatized oligonucleotides having improved uptake |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP92923139A Expired - Lifetime EP0724447B1 (en) | 1991-10-24 | 1992-10-23 | Derivatized oligonucleotides having improved uptake |
Country Status (7)
Country | Link |
---|---|
EP (2) | EP1331011A3 (en) |
JP (1) | JP2823959B2 (en) |
AT (1) | ATE239484T1 (en) |
AU (1) | AU2916292A (en) |
CA (1) | CA2122030C (en) |
DE (1) | DE69233046T2 (en) |
WO (1) | WO1993007883A1 (en) |
Families Citing this family (199)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5688488A (en) * | 1989-04-03 | 1997-11-18 | Purdue Research Foundation | Composition and method for tumor imaging |
US5457189A (en) * | 1989-12-04 | 1995-10-10 | Isis Pharmaceuticals | Antisense oligonucleotide inhibition of papillomavirus |
US6395492B1 (en) | 1990-01-11 | 2002-05-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
US5578718A (en) * | 1990-01-11 | 1996-11-26 | Isis Pharmaceuticals, Inc. | Thiol-derivatized nucleosides |
US6399754B1 (en) | 1991-12-24 | 2002-06-04 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides |
US6060592A (en) | 1990-01-11 | 2000-05-09 | Isis Pharmaceuticals, Inc. | Pyrimidine nucleoside compounds and oligonucleoside compounds containing same |
US6114513A (en) * | 1990-01-11 | 2000-09-05 | Isis Pharmaceuticals, Inc. | Thiol-derivatized oligonucleotides |
US5688941A (en) * | 1990-07-27 | 1997-11-18 | Isis Pharmaceuticals, Inc. | Methods of making conjugated 4' desmethyl nucleoside analog compounds |
US5998603A (en) * | 1994-09-29 | 1999-12-07 | Isis Pharmaceuticals, Inc. | 4'-desmethyl nucleoside analogs, and oligomers thereof |
US5608046A (en) * | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
US7223833B1 (en) | 1991-05-24 | 2007-05-29 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid conjugates |
US6713602B1 (en) | 1991-05-24 | 2004-03-30 | Ole Buchardt | Synthetic procedures for peptide nucleic acids |
US5607691A (en) * | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
US6071699A (en) | 1996-06-07 | 2000-06-06 | California Institute Of Technology | Nucleic acid mediated electron transfer |
US5886177A (en) * | 1994-01-11 | 1999-03-23 | Isis Pharmaceuticals, Inc. | Phosphate linked oligomers |
US6448373B1 (en) | 1994-01-11 | 2002-09-10 | Isis Pharmaceuticals, Inc. | Phosphate linked oligomers formed of monomeric diols and processes for preparing same |
US6184389B1 (en) | 1994-01-11 | 2001-02-06 | Isis Pharmaceuticals, Inc. | Combinatorial libraries having aminodiol monomer subunits |
US6828427B1 (en) | 1994-01-11 | 2004-12-07 | Isis Pharmaceuticals, Inc. | Oligomeric aminodiol-containing compounds, libraries thereof, and process of preparing the same |
US5637684A (en) * | 1994-02-23 | 1997-06-10 | Isis Pharmaceuticals, Inc. | Phosphoramidate and phosphorothioamidate oligomeric compounds |
US5646269A (en) * | 1994-04-28 | 1997-07-08 | Gilead Sciences, Inc. | Method for oligonucleotide analog synthesis |
US6468981B1 (en) * | 1994-07-29 | 2002-10-22 | Emory University | Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors |
AUPM747694A0 (en) * | 1994-08-16 | 1994-09-08 | Commonwealth Scientific And Industrial Research Organisation | Delivery of nucleic acids and peptides |
FR2727970A1 (en) * | 1994-12-12 | 1996-06-14 | Inst Nat Sante Rech Med | FULLERENE-OLIGONUCLEOTIDE, OR FULLERENE-NUCLEOTIDE CONJUGATES THEIR COMPLEXES WITH NANOPARTICLES AND THEIR THERAPEUTIC USES |
JPH10512894A (en) * | 1995-03-06 | 1998-12-08 | アイシス・ファーマシューティカルス・インコーポレーテッド | Improved method for the synthesis of 2'-O-substituted pyrimidines and their oligomeric compounds |
US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
WO1997023497A1 (en) * | 1995-12-22 | 1997-07-03 | University Technologies International Inc. | Linker arm for solid support oligonucleotide synthesis and process for production thereof |
US5834198A (en) * | 1996-03-21 | 1998-11-10 | Boehringer Mamnnheim Gmbh | Selective photoinducted flavin-dependent cleavage of RNA at G-U base pairs and kits therefor |
US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
DK0906329T3 (en) * | 1996-06-06 | 2004-02-09 | Novartis Ag | 2'-Substituted nucleosides and oligonucleotide derivatives |
US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
US6977244B2 (en) | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
EP0856579A1 (en) * | 1997-01-31 | 1998-08-05 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | An antisense oligonucleotide preparation method |
PL336231A1 (en) | 1997-02-13 | 2000-06-19 | Bone Care International | System for aimed therapeutic delivery of vitamin d compounds |
US6576752B1 (en) | 1997-02-14 | 2003-06-10 | Isis Pharmaceuticals, Inc. | Aminooxy functionalized oligomers |
US6172209B1 (en) | 1997-02-14 | 2001-01-09 | Isis Pharmaceuticals Inc. | Aminooxy-modified oligonucleotides and methods for making same |
US6127533A (en) | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
AU9377498A (en) | 1997-09-05 | 1999-03-22 | Isis Pharmaceuticals, Inc. | Substituted cyclic compounds and mixtures comprising same |
US7572582B2 (en) | 1997-09-12 | 2009-08-11 | Exiqon A/S | Oligonucleotide analogues |
US7285288B1 (en) | 1997-10-03 | 2007-10-23 | Board Of Regents, The University Of Texas System | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
US7704962B1 (en) | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
US6232463B1 (en) | 1997-10-09 | 2001-05-15 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
AU4328399A (en) * | 1998-06-15 | 2000-01-05 | Alza Corporation | Nucleic acid-cobalamin complexes and their use in gene therapy |
CA2336384A1 (en) * | 1998-07-02 | 2000-01-13 | The Trustees Of Columbia University In The City Of New York | Oligonucleotide inhibitors of bcl-xl |
EP1091972A1 (en) * | 1998-07-02 | 2001-04-18 | University Technologies International Inc. | Reusable solid support for oligonucleotide synthesis |
US6277967B1 (en) | 1998-07-14 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages |
SE9803099D0 (en) | 1998-09-13 | 1998-09-13 | Karolinska Innovations Ab | Nucleic acid transfer |
US6403779B1 (en) | 1999-01-08 | 2002-06-11 | Isis Pharmaceuticals, Inc. | Regioselective synthesis of 2′-O-modified nucleosides |
ATE356824T1 (en) | 1999-05-04 | 2007-04-15 | Santaris Pharma As | L-RIBO-LNA ANALOGUE |
US6656730B1 (en) * | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
US6277982B1 (en) | 1999-08-20 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Alkylation of alcohols, amines, thiols and their derivatives by cyclic sulfate intermediates |
US6809195B1 (en) | 2000-08-16 | 2004-10-26 | Isis Pharmaceuticals, Inc. | Process for the preparation of oligonucleotides |
DE10048091A1 (en) * | 2000-09-28 | 2002-04-25 | Ernst Bayer | Use of chemically modified oligodeoxyribonucleotides to suppress the proliferation of human pancreatic tumors |
WO2002045707A2 (en) * | 2000-12-06 | 2002-06-13 | Lyles Mark B | Polynucleotide intercalator interceptors and inhibitors |
US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US6878805B2 (en) | 2002-08-16 | 2005-04-12 | Isis Pharmaceuticals, Inc. | Peptide-conjugated oligomeric compounds |
DK1563100T3 (en) * | 2002-11-01 | 2013-08-05 | Iris Int Inc | Displacement sandwich-immuno-PCR |
US9150605B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
WO2004044132A2 (en) | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Modified oligonucleotides for use in rna interference |
US9150606B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
US6913890B2 (en) | 2002-12-18 | 2005-07-05 | Palo Alto Research Center Incorporated | Process for preparing albumin protein conjugated oligonucleotide probes |
EP1633770B1 (en) | 2003-06-13 | 2015-04-29 | Alnylam Europe AG | Double-stranded ribonucleic acid with increased effectiveness in an organism |
JP4584987B2 (en) * | 2004-04-30 | 2010-11-24 | アルニラム ファーマスーティカルズ インコーポレイテッド | Oligonucleotides containing C5-modified pyrimidines |
US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
US7632932B2 (en) * | 2004-08-04 | 2009-12-15 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase |
US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
ATE530666T1 (en) | 2004-11-03 | 2011-11-15 | Iris Molecular Diagnostics Inc | MICROBUBBLES FOR AFFINITY SEPARATION |
CN103146808A (en) | 2004-11-03 | 2013-06-12 | 意力速分子诊断股份有限公司 | Homogeneous analyte detection |
WO2006138145A1 (en) | 2005-06-14 | 2006-12-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
US7320965B2 (en) | 2005-10-28 | 2008-01-22 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Huntingtin gene |
AU2006311725B2 (en) | 2005-11-04 | 2011-11-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of NAV1.8 gene |
EP2363134B1 (en) | 2005-11-09 | 2014-01-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of factor V Leiden mutant gene |
EP2388328A1 (en) | 2006-01-27 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of micrornas |
CN101484588B (en) | 2006-05-11 | 2013-11-06 | 阿尔尼拉姆医药品有限公司 | Compositions and methods for inhibiting expression of the pcsk9 gene |
CA2663581C (en) | 2006-09-21 | 2016-03-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the hamp gene |
AU2007303205A1 (en) | 2006-10-03 | 2008-04-10 | Tekmira Pharmaceuticals Corporation | Lipid containing formulations |
WO2008098248A2 (en) | 2007-02-09 | 2008-08-14 | Northwestern University | Particles for detecting intracellular targets |
PE20090064A1 (en) | 2007-03-26 | 2009-03-02 | Novartis Ag | DOUBLE-CHAIN RIBONUCLEIC ACID TO INHIBIT THE EXPRESSION OF THE HUMAN E6AP GENE AND THE PHARMACEUTICAL COMPOSITION THAT INCLUDES IT |
CA3055145A1 (en) | 2007-05-30 | 2008-12-11 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
CA2692503C (en) | 2007-07-05 | 2013-09-24 | Novartis Ag | Dsrna for treating viral infection |
WO2009060122A2 (en) * | 2007-11-05 | 2009-05-14 | Baltic Technology Development, Ltd. | Use of oligonucleotides with modified bases as antiviral agents |
FR2931152B1 (en) * | 2008-05-16 | 2010-07-30 | Centre Nat Rech Scient | NEW NUCLEIC ACID TRANSFER SYSTEM |
CN106955360A (en) | 2008-11-24 | 2017-07-18 | 西北大学 | Polyvalent RNA-nanoparticle compositions |
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
KR20110100316A (en) | 2009-02-03 | 2011-09-09 | 에프. 호프만-라 로슈 아게 | Compositions and methods for inhibiting expression of ptp1b genes |
AP3574A (en) | 2009-08-14 | 2016-02-08 | Alnylam Pharmaceuticals Inc | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus |
EP3252068A3 (en) | 2009-10-12 | 2018-03-14 | Larry J. Smith | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
JP5866119B2 (en) | 2009-10-30 | 2016-02-17 | ノースウェスタン ユニバーシティ | Template nanocomposite |
AR078921A1 (en) | 2009-11-09 | 2011-12-14 | Hoffmann La Roche | COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF GENES OF THE QUINESINAS SUPERFAMILY, KIF10 |
US20110152349A1 (en) | 2009-12-18 | 2011-06-23 | Anke Geick | Compositions and methods for inhibiting expression of il-18 genes |
US20110196016A1 (en) | 2010-02-05 | 2011-08-11 | Anke Geick | Compositions and Methods for Inhibiting Expression of IKK2 Genes |
EP3210611B1 (en) | 2010-03-12 | 2019-08-21 | The Brigham and Women's Hospital, Inc. | Methods of treating vascular inflammatory disorders |
NZ603339A (en) | 2010-04-29 | 2015-01-30 | Isis Pharmaceuticals Inc | Modulation of transthyretin expression |
EP2630240A1 (en) | 2010-10-18 | 2013-08-28 | Arrowhead Research Corporation | Compositions and methods for inhibiting expression of rrm2 genes |
TWI695066B (en) | 2011-06-30 | 2020-06-01 | 美商艾羅海德製藥公司 | Compositions and methods for inhibiting gene expression of hepatitis b virus |
ES2856091T3 (en) | 2011-09-14 | 2021-09-27 | Univ Northwestern | Nanoconjugates capable of crossing the blood-brain barrier |
JP2015502365A (en) | 2011-12-12 | 2015-01-22 | オンコイミューニン,インコーポレイティド | In vivo delivery of oligonucleotides |
WO2013163628A2 (en) | 2012-04-27 | 2013-10-31 | Duke University | Genetic correction of mutated genes |
KR102238317B1 (en) | 2012-05-17 | 2021-04-12 | 익스텐드 바이오사이언시즈, 인크. | Carriers for improved drug delivery |
AU2013346767B2 (en) | 2012-11-15 | 2019-04-11 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
RU2018108405A (en) | 2013-01-30 | 2019-02-26 | Ф. Хоффманн-Ля Рош Аг | CARBOHYDRATE AND LNA-OLIGONUCLEOTIDE CONJUGATES |
PE20160158A1 (en) | 2013-06-27 | 2016-03-18 | Roche Innovation Ct Copenhagen As | ANTI-SENSE AND CONJUGATED OLIGOMERS WITH TARGET IN PCSK9 |
US10036020B2 (en) | 2013-09-19 | 2018-07-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Compositions and methods for inhibiting JC virus (JCV) |
JP6694811B2 (en) | 2013-10-04 | 2020-05-20 | ノバルティス アーゲー | 3'end cap for RNAi agents for use in RNA interference |
JP6546161B2 (en) | 2013-10-04 | 2019-07-17 | ノバルティス アーゲー | Organic compounds for treating hepatitis B virus |
US9988627B2 (en) | 2013-10-04 | 2018-06-05 | Novartis Ag | Formats for organic compounds for use in RNA interference |
CA2844640A1 (en) | 2013-12-06 | 2015-06-06 | The University Of British Columbia | Method for treatment of castration-resistant prostate cancer |
TR201908550T4 (en) | 2014-06-04 | 2019-07-22 | Exicure Inc | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications. |
TW201620526A (en) | 2014-06-17 | 2016-06-16 | 愛羅海德研究公司 | Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin |
US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
AU2015349680A1 (en) | 2014-11-21 | 2017-06-08 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
WO2016130600A2 (en) | 2015-02-09 | 2016-08-18 | Duke University | Compositions and methods for epigenome editing |
WO2016164463A1 (en) | 2015-04-07 | 2016-10-13 | The General Hospital Corporation | Methods for reactivating genes on the inactive x chromosome |
EP3332007A4 (en) | 2015-08-07 | 2019-07-17 | Arrowhead Pharmaceuticals, Inc. | Rnai therapy for hepatitis b virus infection |
EP4089175A1 (en) | 2015-10-13 | 2022-11-16 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
WO2017068087A1 (en) | 2015-10-22 | 2017-04-27 | Roche Innovation Center Copenhagen A/S | Oligonucleotide detection method |
WO2017075670A1 (en) | 2015-11-05 | 2017-05-11 | Children's Hospital Los Angeles | "mobilizing leukemia cells" |
MX2018005332A (en) | 2015-11-06 | 2018-11-09 | Crispr Therapeutics Ag | Materials and methods for treatment of glycogen storage disease type 1a. |
RS61529B9 (en) | 2015-11-12 | 2024-04-30 | Hoffmann La Roche | Oligonucleotides for inducing paternal ube3a expression |
AU2016355178B9 (en) | 2015-11-19 | 2019-05-30 | Massachusetts Institute Of Technology | Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity |
US11851653B2 (en) | 2015-12-01 | 2023-12-26 | Crispr Therapeutics Ag | Materials and methods for treatment of alpha-1 antitrypsin deficiency |
US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
JP6748219B2 (en) | 2016-03-14 | 2020-08-26 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Oligonucleotide for PD-L1 expression reduction |
EP3429632B1 (en) | 2016-03-16 | 2023-01-04 | CRISPR Therapeutics AG | Materials and methods for treatment of hereditary haemochromatosis |
MA45496A (en) | 2016-06-17 | 2019-04-24 | Hoffmann La Roche | NUCLEIC ACID MOLECULES FOR PADD5 OR PAD7 MRNA REDUCTION FOR TREATMENT OF HEPATITIS B INFECTION |
US11174469B2 (en) | 2016-06-29 | 2021-11-16 | Crispr Therapeutics Ag | Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders |
WO2018002783A1 (en) | 2016-06-29 | 2018-01-04 | Crispr Therapeutics Ag | Materials and methods for treatment of friedreich ataxia and other related disorders |
WO2018002812A1 (en) | 2016-06-29 | 2018-01-04 | Crispr Therapeutics Ag | Materials and methods for treatment of myotonic dystrophy type 1 (dm1) and other related disorders |
WO2018007980A1 (en) | 2016-07-06 | 2018-01-11 | Crispr Therapeutics Ag | Materials and methods for treatment of pain related disorders |
WO2018007976A1 (en) | 2016-07-06 | 2018-01-11 | Crispr Therapeutics Ag | Materials and methods for treatment of pain related disorders |
WO2018007871A1 (en) | 2016-07-08 | 2018-01-11 | Crispr Therapeutics Ag | Materials and methods for treatment of transthyretin amyloidosis |
WO2018020323A2 (en) | 2016-07-25 | 2018-02-01 | Crispr Therapeutics Ag | Materials and methods for treatment of fatty acid disorders |
JOP20170161A1 (en) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | RNAi Agents for Hepatitis B Virus Infection |
US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
AU2017378153B2 (en) | 2016-12-13 | 2024-03-28 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo |
EP3568482A4 (en) | 2017-01-10 | 2020-12-16 | Arrowhead Pharmaceuticals, Inc. | Alpha-1 antitrypsin (aat) rnai agents, compositions including aat rnai agents, and methods of use |
US20190367920A1 (en) | 2017-01-13 | 2019-12-05 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides for modulating nfkb1 expression |
WO2018130585A1 (en) | 2017-01-13 | 2018-07-19 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides for modulating relb expression |
US20190345495A1 (en) | 2017-01-13 | 2019-11-14 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides for modulating nfkb2 expression |
EP3568477A1 (en) | 2017-01-13 | 2019-11-20 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides for modulating rela expression |
EP3568478A1 (en) | 2017-01-13 | 2019-11-20 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides for modulating rel expression |
EP3585898A1 (en) | 2017-02-22 | 2020-01-01 | CRISPR Therapeutics AG | Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders |
WO2018154459A1 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders |
US11920148B2 (en) | 2017-02-22 | 2024-03-05 | Crispr Therapeutics Ag | Compositions and methods for gene editing |
EP3585807A1 (en) | 2017-02-22 | 2020-01-01 | CRISPR Therapeutics AG | Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders |
WO2018154462A2 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders |
WO2019030313A2 (en) | 2017-08-11 | 2019-02-14 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating ube3c expression |
WO2019038228A1 (en) | 2017-08-22 | 2019-02-28 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating tom1 expression |
EP3694995A1 (en) | 2017-10-13 | 2020-08-19 | Roche Innovation Center Copenhagen A/S | Methods for identifying improved stereodefined phosphorothioate oligonucleotide variants of antisense oligonucleotides utilising sub-libraries of partially stereodefined oligonucleotides |
AU2018350693B2 (en) | 2017-10-16 | 2021-03-04 | F. Hoffmann-La Roche Ag | Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection |
MA50877A (en) | 2017-11-21 | 2020-09-30 | Bayer Healthcare Llc | MATERIALS AND METHODS FOR THE TREATMENT OF AUTOSOMIC DOMINANT PIGMENTAL RETINITIS |
MX2020005680A (en) | 2017-12-01 | 2020-08-20 | Texas A & M Univ Sys | Angelman syndrome antisense treatment. |
WO2019115416A2 (en) | 2017-12-11 | 2019-06-20 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating fndc3b expression |
WO2019115417A2 (en) | 2017-12-12 | 2019-06-20 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating rb1 expression |
CN111836892A (en) | 2017-12-21 | 2020-10-27 | 克里斯珀医疗股份公司 | Materials and methods for treating type 2A uker syndrome |
MX2020005872A (en) | 2017-12-21 | 2020-08-13 | Hoffmann La Roche | Companion diagnostic for htra1 rna antagonists. |
KR20200104345A (en) | 2017-12-22 | 2020-09-03 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | Oligonucleotides Containing Phosphorodithioate Internucleoside Linkages |
EP4092117A1 (en) | 2017-12-22 | 2022-11-23 | Roche Innovation Center Copenhagen A/S | Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage |
EP4092118A1 (en) | 2017-12-22 | 2022-11-23 | Roche Innovation Center Copenhagen A/S | Novel thiophosphoramidites |
WO2019137883A1 (en) | 2018-01-10 | 2019-07-18 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating pias4 expression |
CA3085964A1 (en) | 2018-01-12 | 2019-07-18 | Roche Innovation Center Copenhagen A/S | Alpha-synuclein antisense oligonucleotides and uses thereof |
PE20201501A1 (en) | 2018-01-12 | 2020-12-29 | Bristol Myers Squibb Co | ANTI-SENSE OLIGONUCLEOTIDES ACTING ON ALPHA-SINUCLEIN, AND USES OF THESE |
US20210095275A1 (en) | 2018-01-12 | 2021-04-01 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating gsk3b expression |
KR20200140240A (en) | 2018-01-12 | 2020-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
EP3740574A1 (en) | 2018-01-17 | 2020-11-25 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating erc1 expression |
WO2019145386A1 (en) | 2018-01-26 | 2019-08-01 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating csnk1d expression |
JP7500426B2 (en) | 2018-02-21 | 2024-06-17 | ブリストル-マイヤーズ スクイブ カンパニー | CAMK2D ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF |
MA52661A (en) | 2018-04-05 | 2021-02-17 | Centre Leon Berard | USE OF FUBP1 INHIBITORS IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION |
AU2019260687B2 (en) | 2018-04-27 | 2022-09-22 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Rapamycin resistant cells |
JP7102557B2 (en) | 2018-07-03 | 2022-07-19 | エフ.ホフマン-ラ ロシュ アーゲー | Oligonucleotide for TAU expression regulation |
SG11202100348SA (en) | 2018-07-13 | 2021-02-25 | Hoffmann La Roche | Oligonucleotides for modulating rtel1 expression |
AU2019313443A1 (en) | 2018-07-31 | 2020-11-26 | Roche Innovation Center Copenhagen A/S | Oligonucleotides comprising a phosphorotrithioate internucleoside linkage |
AU2019313527A1 (en) | 2018-07-31 | 2021-02-11 | Roche Innovation Center Copenhagen A/S | Oligonucleotides comprising a phosphorotrithioate internucleoside linkage |
JP2022521510A (en) | 2019-02-20 | 2022-04-08 | ロシュ イノベーション センター コペンハーゲン エーエス | Phosphonoacetate gapmer type oligonucleotide |
WO2020169696A1 (en) | 2019-02-20 | 2020-08-27 | Roche Innovation Center Copenhagen A/S | Novel phosphoramidites |
CA3132178A1 (en) | 2019-04-02 | 2020-10-08 | Aliye Seda Yilmaz-Elis | Antisense oligonucleotides for immunotherapy |
BR112021019182A2 (en) | 2019-04-03 | 2022-05-31 | Bristol Myers Squibb Co | Antisense angptl2 oligonucleotides and their uses |
JP2022536945A (en) | 2019-06-18 | 2022-08-22 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | Combination of hepatitis B virus (HBV) vaccine and RNAi targeting HBV |
EP3986456A1 (en) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai |
CN114729392A (en) | 2019-09-06 | 2022-07-08 | 10X基因组学有限公司 | Systems and methods for barcoding cells and cell beads |
WO2021122944A1 (en) | 2019-12-18 | 2021-06-24 | Alia Therapeutics Srl | Compositions and methods for treating retinitis pigmentosa |
EP4294445A1 (en) | 2021-02-19 | 2023-12-27 | Pfizer Inc. | Methods of protecting rna |
US20240141340A1 (en) | 2021-03-05 | 2024-05-02 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for use in the treatment of corneal dystrophies |
PE20240696A1 (en) | 2021-03-08 | 2024-04-10 | Servier Lab | ANTISENSE OLIGONUCLEOTIDES TO INHIBIT THE EXPRESSION OF ALPHA-SINUCLEIN |
WO2023285431A1 (en) | 2021-07-12 | 2023-01-19 | Alia Therapeutics Srl | Compositions and methods for allele specific treatment of retinitis pigmentosa |
WO2023043220A1 (en) | 2021-09-16 | 2023-03-23 | 주식회사 큐마인 | Antisense compound that regulates expression of wfdc2 |
CA3237658A1 (en) | 2021-10-08 | 2023-04-13 | Pfizer Inc. | Immunogenic lnp compositions and methods thereof |
WO2023089556A1 (en) | 2021-11-22 | 2023-05-25 | Pfizer Inc. | Reducing risk of antigen mimicry in immunogenic medicaments |
WO2023111210A1 (en) | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Combination of oligonucleotides for modulating rtel1 and fubp1 |
WO2023118349A1 (en) | 2021-12-21 | 2023-06-29 | Alia Therapeutics Srl | Type ii cas proteins and applications thereof |
WO2023144779A1 (en) | 2022-01-28 | 2023-08-03 | Pfizer Inc. | Coronavirus antigen variants |
WO2023194359A1 (en) | 2022-04-04 | 2023-10-12 | Alia Therapeutics Srl | Compositions and methods for treatment of usher syndrome type 2a |
WO2023233290A1 (en) | 2022-05-31 | 2023-12-07 | Janssen Sciences Ireland Unlimited Company | Rnai agents targeting pd-l1 |
WO2024028794A1 (en) | 2022-08-02 | 2024-02-08 | Temple Therapeutics BV | Methods for treating endometrial and ovarian hyperproliferative disorders |
WO2024056880A2 (en) | 2022-09-16 | 2024-03-21 | Alia Therapeutics Srl | Enqp type ii cas proteins and applications thereof |
WO2024105162A1 (en) | 2022-11-16 | 2024-05-23 | Alia Therapeutics Srl | Type ii cas proteins and applications thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991010671A1 (en) * | 1990-01-11 | 1991-07-25 | Isis Pharmaceuticals, Inc. | Compositions and methods for detecting and modulating rna activity and gene expression |
WO1991014696A1 (en) * | 1990-03-29 | 1991-10-03 | Gilead Sciences, Inc. | Oligonucleotide-transport agent disulfide conjugates |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4958013A (en) * | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
WO1995006659A1 (en) * | 1992-07-01 | 1995-03-09 | Isis Pharmaceuticals, Inc. | Amine-derivatized nucleosides and oligonucleosides |
AU4848793A (en) * | 1992-09-11 | 1994-04-12 | Isis Pharmaceuticals, Inc. | Oligonucleotide and nucleotide amine analogs, methods of synthesis and use |
-
1992
- 1992-10-23 EP EP03076286A patent/EP1331011A3/en not_active Withdrawn
- 1992-10-23 JP JP5507961A patent/JP2823959B2/en not_active Expired - Fee Related
- 1992-10-23 AT AT92923139T patent/ATE239484T1/en not_active IP Right Cessation
- 1992-10-23 CA CA002122030A patent/CA2122030C/en not_active Expired - Lifetime
- 1992-10-23 AU AU29162/92A patent/AU2916292A/en not_active Abandoned
- 1992-10-23 DE DE69233046T patent/DE69233046T2/en not_active Expired - Lifetime
- 1992-10-23 EP EP92923139A patent/EP0724447B1/en not_active Expired - Lifetime
- 1992-10-23 WO PCT/US1992/009196 patent/WO1993007883A1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991010671A1 (en) * | 1990-01-11 | 1991-07-25 | Isis Pharmaceuticals, Inc. | Compositions and methods for detecting and modulating rna activity and gene expression |
WO1991014696A1 (en) * | 1990-03-29 | 1991-10-03 | Gilead Sciences, Inc. | Oligonucleotide-transport agent disulfide conjugates |
Non-Patent Citations (6)
Title |
---|
CHING-HSUAN TUNG ET AL: "PREPARATION OF OLIGONUCLEOTIDE-PEPTIDE CONJUGATES", BIOCONJUGATE CHEMISTRY, vol. 2, no. 6, 1 November 1991 (1991-11-01), pages 464 - 465, XP000235497 * |
ENGLISCH U ET AL: "CHEMICALLY MODIFIED OLIGONUCLEOTIDES AS PROBES AND INHIBITORS", ANGEWANDTE CHEMIE. INTERNATIONAL EDITION, vol. 30, no. 6, 1 June 1991 (1991-06-01), pages 613 - 629, XP000218347 * |
GOODCHILD J: "CONJUGATES OF OLIGONUCLEOTIDES AND MODIFIED OLIGONUCLEOTIDES: A REVIEW OF THEIR SYNTHESIS AND PROPERTIES", BIOCONJUGATE CHEMISTRY, vol. 1, no. 3, 1 May 1990 (1990-05-01), pages 165 - 187, XP000174627 * |
LESZEK CZUCHAJOWSKI: "PORPHYRINYL-URIDINES AS THE FIRST WATER SOLUBLE PORPHYRINYL- NUCLEOSIDES", TETRAHEDRON LETTERS, vol. 32, no. 51, 16 December 1991 (1991-12-16), pages 7511 - 7512, XP000247164 * |
MANOHARAN M ET AL: "CHEMICAL MODIFICATIONS TO IMPROVE UPTAKE AND BIOAVAILABILITY OF ANTISENSE OLIGONUCLEOTIDES", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES, NEW YORK, NY, US, vol. 660, 1992, pages 306 - 309, XP000198020, ISSN: 0077-8923 * |
MANOHARAN, GUINOSSO ET AL: "Novel functionalization of the sugar moiety of nucleic acids for multiple labeling in the minor groove", TETRAHEDRON LETT. (1991), 32(49), 7171-4 CODEN: TELEAY;ISSN: 0040-4039, 1991, XP002258381 * |
Also Published As
Publication number | Publication date |
---|---|
EP0724447A1 (en) | 1996-08-07 |
EP0724447B1 (en) | 2003-05-07 |
EP1331011A2 (en) | 2003-07-30 |
CA2122030C (en) | 1997-03-04 |
CA2122030A1 (en) | 1993-04-29 |
JP2823959B2 (en) | 1998-11-11 |
DE69233046D1 (en) | 2003-06-12 |
WO1993007883A1 (en) | 1993-04-29 |
EP0724447A4 (en) | 1996-01-22 |
ATE239484T1 (en) | 2003-05-15 |
AU2916292A (en) | 1993-05-21 |
DE69233046T2 (en) | 2004-03-04 |
JPH06510791A (en) | 1994-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2916292A (en) | Derivatized oligonucleotides having improved uptake and other properties | |
AU7683394A (en) | Thiol-derivatized nucleosides and oligonucleosides | |
CA2333875A1 (en) | Redox reversible bipyridyl osmium complex conjugates | |
CA2134239A1 (en) | Pretargeting methods and compounds | |
NO996107L (en) | C-4 "-substituted macrolide derivatives | |
Kappen et al. | Identification of thymidine-5′-aldehyde at DNA strand breaks induced by neocarzinostatin chromophore | |
WO1991012023A3 (en) | Hybrid reagents capable of selectively releasing molecules into cells | |
FR2714907B1 (en) | New adenosine derivatives, their preparation processes, pharmaceutical compositions containing them. | |
CA2098882A1 (en) | Process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-d-ribofuranosyl sulfonates | |
MX9303708A (en) | STEREOSELECTIVE ANIONIC GLUCOSILATION PROCESS TO PREPARE 2'-DEOXIFLUORO-BETA NUCLEOSIDES. | |
IE46107L (en) | Pyrimidine nucleosides | |
AU1079499A (en) | Improved synthesis of sulfurized oligonucleotides | |
ATE223461T1 (en) | HELIUM-NEON STIMULATABLE RETICULOCITE DYES AVAILABLE FROM HALOLEPIDINES | |
Kovacic et al. | DNA molecular electrostatic potential: novel perspectives for the mechanism of action of anticancer drugs involving electron transfer and oxidative stress | |
PT778844E (en) | FUNCTIONAL COMPLEXES OF TERPYRIDINE METALS PROCESSES FOR THEIR PREPARATION AND OLIGONUCLEOTIDE CONJUGATES WITH TERPYRIDINE METAL COMPLEXES | |
KR920701220A (en) | New binuclear platinum complex and antitumor agent using the same | |
IE45070L (en) | Anthracycline glycoside antibiotics | |
WO1994012518A2 (en) | Reagent for coupling various substances to nucleic acids, and a method of preparing the reagent | |
DE3800644A1 (en) | PROCESS FOR HIGHLY SPECIFIC DETECTION OF NUCLEIC ACIDS IN SOLUTION | |
EP0305972A3 (en) | 3'- demethoxyepipodophyllotoxin glucoside derivatives | |
Ichikawa et al. | Simple preparation of multi-valent cyclodextrin–carbohydrate conjugates | |
CA2227491A1 (en) | In situ preparation of nucleoside phosphoramidites and oligonucleotide synthesis | |
Lüstorff et al. | Does an inhibitor of mitochondrial adenylate kinase also affect oxidative phosphorylation? | |
WO1998004575A3 (en) | Lipophilic oligonucleotide analogs | |
AU2739797A (en) | (in situ) preparation of nucleoside phosphoramidites and their use in synthesis of oligonucleotides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 0724447 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: COOK, PHILIP DAN Inventor name: BENNET, CLARENCE FRANK Inventor name: MANOHARAN, MUTHIAH |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61K 31/70 A Ipc: 7C 07H 21/00 B Ipc: 7A 61K 47/48 B |
|
17P | Request for examination filed |
Effective date: 20040507 |
|
AKX | Designation fees paid |
Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ISIS PHARMACEUTICALS, INC. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20060503 |